ClinicalTrials.gg
CompletedNCT01079143CERTITEMUpdated Mar 18, 2014Results posted

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

A Phase 3 interventional study of Certican® and Neoral in Renal Interstitial Fibrosis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in France. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-03-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

Recently, early biomarkers of renal interstitial fibrosis have been identified, amongst them de novo expression of vimentin by tubular epithelial cells, which is an intermediate filament, and the translocation of beta-catenin into their cytoplasm. These markers, when present, suggest that the epithelial cell undergoes a phenomenon well known as "epithelial to mesenchymal transition" (EMT) and could behaves like a myo-fibroblast. EMT is highly instrumental in several models of tissue fibrosis, including in the kidney. Actually, it has not only been demonstrated that these markers are detectable in the renal graft at an early time point post-transplant (i.e. as soon as three months), but also that the intensity of their expression correlates with the progression of interstitial fibrosis of the graft between 3 and 12 months

02

Conditions studied

  • Renal Interstitial Fibrosis

Keywords

  • De Novo renal transplantation
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recipient of a primary or secondary deceased or living (related or not) donor kidney transplant and who requires basiliximab induction therapy.
  • Cold ischemia time \< 30 hours.
  • Women of child-bearing age, even those with a history of infertility, must have had a negative pregnancy test during the 7 days before screening or at the time of screening, and must use a recognized and reliable method of throughout the study and for 2 months after discontinuing the study treatment.
  • Patients who want and are able to take part in the entire study, and have given their written consent.
  • Patients who are registered with a French national health insurance scheme or are covered by such a scheme.

Exclusion criteria

Exclusion Criteria:

  • Recipient of multi-organ transplantation, including dual kidneys, or who have previously received non renal transplant organ.
  • Patients receiving a graft from a non-heart-beating donor.
  • Anti-HLA antibody levels ≥ 20% in the last 3 months before the inclusion.
  • ABO incompatible graft or with positive cross match T.
  • Severe hyperlipidemia: total cholesterol ≥ 9.1 mmol/L (≥ 350 mg/dL) and/or triglycerides ≥ 8.5 mmol/L (≥ 750 mg/dL) despite appropriate lipid-lowering therapy.
  • Known or to mycophenolic acid, cyclosporine or lactose.
  • Known hypersensitivity or contraindications to macrolides or drugs of the mTOR inhibitor class.
  • seropositive, or active chronic (HBs Ab) or C. Results obtained during the 6 months before the inclusion are accepted. Recipients from donors with hepatitis B or C will be excluded.
  • Patients with thrombocytopenia (≤ 75000/mm3), (≤ 1500/mm3), leukocytopenia (≤ 2500/mm3) and/or \< 8g/dL at the inclusion visit.
  • ASAT, ALAT or total ≥ 3 UNL.
  • Uncontrolled severe infection, severe allergy requiring an acute or chronic treatment.
  • Patients with a malignant disease or previous in the past 5 years, with the exception of excised basal cell or squamous cell carcinoma and in situ cervical cancer treated.
  • Medical or surgical condition, with the exception of the transplantation, which in the investigator's opinion could exclude the patient.
  • Women who are pregnant, breastfeeding or of reproductive age and refuse or are unable to use a recognized and reliable method of .
  • Patients with symptoms of significant mental or somatic disease. Inability to cooperate or communicate with the investigator.
  • Patients under supervision or guardianship or any patient subject to legal protection

Randomization criteria:

Eligibility criteria (no later than 4 months post-transplantation:

  • Renal graft performed at M3 and adequate histological material sent within the deadline for the determination of EMT.
  • Woman of , even in case of a history of infertility, must use a recognized and reliable method of contraception throughout the study and for 2 months after discontinuing the study treatment.

Non-eligibility criteria (no later than 4 months post-transplantation):

  • Acute rejection proven between transplantation and randomization (local reading).
  • Acute subclinical rejection diagnosed on the M3 biopsy (except borderline lesions) (local reading).
  • Positive anti-donor antibodies at M3.
  • Estimated (eGFR) \< 30 ml/min/1.73 m2 (MDRDa).
  • Proteinuria ≥ 1 g/24h.
  • Severe hyperlipidemia: total cholesterol ≥ 9.1 mmol/L (≥ 350 mg/dL) and/or triglycerides ≥ 8.5 mmol/L (≥ 750 mg/dL) despite appropriate lipid-lowering therapy.
  • Thrombocytopenia (≤ 75000/mm3), absolute neutrophil count (≤ 1500/mm3), leukocytopenia (≤ 2500/mm3) and/or hemoglobin \< 8 g/dL.
  • ASAT, ALAT or total bilirubin ≥ 3 UNL.
  • Medical or surgical condition which in the investigator's opinion might exclude the patient.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Certican EMT+

    Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.

    Drug: Certican® · Drug: Myfortic · Drug: Simulect® · Drug: Corticosteroids

  • Experimental
    Certican EMT-

    Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.

    Drug: Certican® · Drug: Myfortic · Drug: Simulect® · Drug: Corticosteroids

  • Active comparator
    Neoral EMT+

    Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.

    Drug: Neoral · Drug: Myfortic · Drug: Simulect® · Drug: Corticosteroids

  • Active comparator
    Neoral EMT-

    Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.

    Drug: Neoral · Drug: Myfortic · Drug: Simulect® · Drug: Corticosteroids

Interventions

  • Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.

    Also known as: Everolimus, RAD001

  • DrugNeoral

    Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.

    Also known as: Cyclosporine

  • Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study. In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study. An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days.

  • The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.

    Also known as: basiliximab

  • DrugCorticosteroids

    An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population

    Progression of Interstitial Fibrosis/Tabular Atrophy (IF/TA) is the percentage (%) of participants with an increase \>= 1 in IF/TA grade according to Banff (2005 - 2007)according to Epithelial-mesenchymal transition (EMT) profile and by treatment groups. Grade I (the better): mild interstitial fibrosis and tubular atrophy (\<25% of cortical area) Grade II : moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area) Grade III (the worse) : severe interstitial fibrosis and tubular atrophy (\>50% of cortical area)

    Time frame: Month 3 (M3) and Month 12 (M12) post transplantation

Secondary outcomes

  1. Interstitial Fibrosis/Tabular Atrophy (IF/TA)

    Incidence and severity of IF/TA according to 2005/2007 Banff classification system grades (grades l to lll). IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (\<25%), grade II (25-50%) and grade III (\>50% of lesions).

    Time frame: M3 and M12 post transplantation

  2. Change in Interstitial Fibrosis/Tabular Atrophy (IF/TA) Grade

    Difference (M12 - M3) in IF/TA grade. IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (\<25%), grade II (25-50%) and grade III (\>50% of lesions).

    Time frame: M3 and M12 post transplantation

  3. Risk Factors of IF/TA Progression

    Composite factors regarding fibrosis progression at 12 months using a logistic regression model; the parameters initially considered concerned the demographic characteristics of both recipient and donor, transplantation characteristics, hypertension, diabetes, study treatments, immunosuppression, EMT, IF/TA, function at M3, the onset of acute rejection, the presence of anti-donor antibodies at M12, infections and BK virus viremia. Arteriolar hyaline thickening is thickening of the walls of arterioles by the deposition of homogeneous pink hyaline material. BPAR is biopsy proven acute rejection. TEM progression is the increase ≥ 1 of TEM score between Month 3 and Month 12

    Time frame: M12 post transplantation

  4. Change in Percentage of Interstitial Fibrosis (IF) by Numerical Quantification

    Percentage of IF measured by numerical quantification. The IF percentage was transposed in grade according to the following rule: grade 0 for an IF % ≤5%, grade I for an IF % ranging from \>5% to \< 25%, grade II for an IF % ranging from 25 to 50%, grade III for an IF % \>50%. Interstitial graft fibrosis has been identified as the primary cause of graft loss following death with a functional graft \[3-5\].

    Time frame: M3 and M12 post transplantation

  5. Number of Participants With Progression of Renal Fibrosis Using Numerical Quantification

    Comparisons according to epithelial-mesenchymal transition (EMT) profile and immunosuppressive treatment

    Time frame: M3 to M12 post transplantation

  6. Number of Participants With Epithelial-mesenchymal Transition (EMT) Status

    Incidence and severity of EMT status. EMT status was determined centrally using the graft biopsy taken at 3 months. The result was quickly obtained (within 7 to 15 days) and sent to the company in charge of randomization in order to allocate each patient to a treatment group and to provide the investigator with this information without confirming EMT status.

    Time frame: M3 and M12 post transplantation

  7. Number of Participants With Epithelial-mesenchymal Transition (EMT) Score

    Incidence and severity of EMT score. The intensity of EMT markers expression present and detectable in the renal graft at an early stage following transplantation is known as EMT score. EMT score 0 (the best): \<1 EMT score 1 (the better): 1-10% of tubular atrophy EMT score 2: 10-25% of tubular atrophy EMT score 3: 25-50% of tubular atrophy EMT score 4 (the worst): \>50% of tubular atrophy

    Time frame: M3 and M12 post transplantation

  8. Change in EMT Score

    Change (M12 - M3) in EMT Score. Progression in EMT score is defined as an increase by \>=1 of EMT score from M3 to M12. EMT score 0 (the best): \<1 EMT score 1 (the better) : 1-10% of tubular atrophy EMT score 2 : 10-25% of tubular atrophy EMT score 3 : 25-50% of tubular atrophy EMT score 4 (the worst): \>50% of tubular atrophy

    Time frame: M3 and M12 post transplantation

  9. Incidence (Number) of Subclinical Rejections and Borderline Lesions

    Incidence of subclinical rejections and borderline lesions with regards to histological evidence of rejection with clinical findings. Subclinical rejections: rejection without clinical symptoms which is diagnosed by chance when a graft biopsy is performed. Clinically suspected BPAR: rejection suspected because of the presence of clinical symptoms (fever, pain, increase of creatinine) and then confirmed by the graft biopsy. Borderline lesions: suspicious for acute T-cell mediated rejection. This category is used when no intimal arteritis is present, but there are foci of tubulitis with minor interstitial infiltration or interstitial infiltration with mild tubulitis.

    Time frame: M3

  10. Change From Baseline (M3) in Estimated Glomerular Filtration Rate (eGFR)

    eGFR was calculated according to the abbreviated Modification of Diet in Renal Disease (MDRD) Formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²). LOCF = Last observation carried forward

    Time frame: M3 (baseline) to M12 post transplantation

  11. Change in Estimated Glomerular Filtration Rate (eGFR) at M12 From Baseline (M3) - ANCOVA Model

    The average patient renal function was evaluated on the basis of eGFR was calculated according to the abbreviated MDRD formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²).

    Time frame: Baseline (M3), M12

  12. Change in Urine Protein/Creatinine Ratio (Without Imputation)

    One of the factors associated with EMT progression between M3 and M12 according to univariate analysis (ITT biopsies M3 \& M12).

    Time frame: Month 3 (baseline), Month 12

  13. Treatment Failures

    A treatment failure is defined as biopsy proven acute rejection (BPAR), a graft loss, a death or a loss to follow up. It was assessed between randomization and 6 and 12 months post-transplantation.

    Time frame: M6 and M12 post transplantation

  14. Type of Biopsy Proven Acute Rejection (BPAR)

    A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. Biopsy graded IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).

    Time frame: M6 and M12 post transplantation

  15. Severity of BPAR

    A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. Biopsy graded IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).

    Time frame: M6 and M12 post transplantation

  16. Incidence (Number) of BPAR

    A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system.

    Time frame: M6 and M12 post transplantation

  17. Incidence (Number) of Participants With Graft Losses

    If a participant underwent a graft nephrectomy, then the day of nephrectomy was considered as the day of graft loss.

    Time frame: M6 and M12 post transplantation

07

Results

Posted Mar 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
Started36603959
Exposed36603959
Month 3 (m3) biopsies36593959
Month 12 (m12) biopsies26433253
M3 and m12 biopsies26433253
Completed27433454
Not completed91755

Outcome measures

PrimaryNumber of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population

Progression of Interstitial Fibrosis/Tabular Atrophy (IF/TA) is the percentage (%) of participants with an increase \>= 1 in IF/TA grade according to Banff (2005 - 2007)according to Epithelial-mesenchymal transition (EMT) profile and by treatment groups. Grade I (the better): mild interstitial fibrosis and tubular atrophy (\<25% of cortical area) Grade II : moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area) Grade III (the worse) : severe interstitial fibrosis and tubular atrophy (\>50% of cortical area)

Time frame:
Month 3 (M3) and Month 12 (M12) post transplantation
Reported as:
Number · Participants
Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population
ParticipantsCertican EMT+Neoral EMT+
Participants with an IF/TA grade <= II at M32631
Participants with Fibrosis progression, M3 to M121216
SecondaryInterstitial Fibrosis/Tabular Atrophy (IF/TA)

Incidence and severity of IF/TA according to 2005/2007 Banff classification system grades (grades l to lll). IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (\<25%), grade II (25-50%) and grade III (\>50% of lesions).

Time frame:
M3 and M12 post transplantation
Reported as:
Number · Number of participants
Interstitial Fibrosis/Tabular Atrophy (IF/TA)
Number of participantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
Interstitial Fibrosis/Tubular Atrophy (IF/TA)13381344
IF/TA grade at M3 at grade 1115179
IFTA grade at M3 at grade II2010
IF/TA grade at M3 at grade III0010
IF/TA grade at M12 at grade 0920731
IT/TA grade at M12 at grade I8181515
IF/TA grade at M12 at grade II6596
IF/TA grade at M12 at grade III3011
SecondaryChange in Interstitial Fibrosis/Tabular Atrophy (IF/TA) Grade

Difference (M12 - M3) in IF/TA grade. IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (\<25%), grade II (25-50%) and grade III (\>50% of lesions).

Time frame:
M3 and M12 post transplantation
Reported as:
Number · Number of Participants
Change in Interstitial Fibrosis/Tabular Atrophy (IF/TA) Grade
Number of ParticipantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
Difference in IF/TA grade -15172
Difference in IF/TA grade 0921933
Difference in IF/TA grade 17181113
Difference in IF/TA grade 23355
Difference in IF/TA grade 32NA0NA
SecondaryRisk Factors of IF/TA Progression

Composite factors regarding fibrosis progression at 12 months using a logistic regression model; the parameters initially considered concerned the demographic characteristics of both recipient and donor, transplantation characteristics, hypertension, diabetes, study treatments, immunosuppression, EMT, IF/TA, function at M3, the onset of acute rejection, the presence of anti-donor antibodies at M12, infections and BK virus viremia. Arteriolar hyaline thickening is thickening of the walls of arterioles by the deposition of homogeneous pink hyaline material. BPAR is biopsy proven acute rejection. TEM progression is the increase ≥ 1 of TEM score between Month 3 and Month 12

Time frame:
M12 post transplantation
Reported as:
Number · Participants
Risk Factors of IF/TA Progression
ParticipantsYes- Fibrosis ProgressionNo- No Fibrosis Progression
Donor Sex - Male4548
Donor Sex - Female2238
Donor Age - <=50 years2848
Donor Age - >50 years3938
Expanded Criteria donor: NO4063
Expanded Criteria Donor: Yes2723
Delayed graft function: No5276
Delayed graft function: Yes1510
CC at M3 <50 mL/min/1.73m^24035
CC at M3 >=50 mL/min/1.73m^2 (n=67, 85)2750
Mesangial matrix increase at M3 - 0 (n=64, 85)5984
Mesangial matrix (mm) increase at M3: 1 (n=64, 85)21
Mesangial matrix increase at M3: 2 (n=64, 85)30
Interstitial fibrosis (ci) at M3: 0 (n=66, 85)5255
Interstitial fibrosis (ci) at M3: 1 (n=66, 85)1427
Interstitial fibrosis (ci) at M3: 2 (n=66, 85)03
Arteriolar hyaline thickening (ah) at M3: 03656
Arteriolar hyaline thickening (ah) at M3: 11521
Arteriolar hyaline thickening (ah) at M3: 2108
Arteriolar hyaline thickening (ah) at M3: 361
BPAR - No5579
BPAR - Yes127
TEM Progression fron M3-M12: No (n=67, 83)2657
TEM Progression fron M3-M12: Yes (n=67, 83)4126
TEM Progression fron M3-M12: Missing (n=67, 83)03
SecondaryChange in Percentage of Interstitial Fibrosis (IF) by Numerical Quantification

Percentage of IF measured by numerical quantification. The IF percentage was transposed in grade according to the following rule: grade 0 for an IF % ≤5%, grade I for an IF % ranging from \>5% to \< 25%, grade II for an IF % ranging from 25 to 50%, grade III for an IF % \>50%. Interstitial graft fibrosis has been identified as the primary cause of graft loss following death with a functional graft \[3-5\].

Time frame:
M3 and M12 post transplantation
Reported as:
Mean · Percentage of IF
Change in Percentage of Interstitial Fibrosis (IF) by Numerical Quantification
Percentage of IFCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
Percentage of IF at M3 (n=26,43,32,53)22.8 ± 8.915.9 ± 7.523.4 ± 9.517.8 ± 8.2
Percentage of IF at M12 (n=24,42,32,53)27.6 ± 12.220.9 ± 10.127.4 ± 11.520.4 ± 9.1
Change in Percentage of IF (n=24,42,32,53)5.1 ± 12.44.9 ± 12.23.9 ± 12.32.7 ± 9.7
SecondaryNumber of Participants With Progression of Renal Fibrosis Using Numerical Quantification

Comparisons according to epithelial-mesenchymal transition (EMT) profile and immunosuppressive treatment

Time frame:
M3 to M12 post transplantation
Reported as:
Number · Participants
Number of Participants With Progression of Renal Fibrosis Using Numerical Quantification
ParticipantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
Fibrosis Progression - No (n=24, 42, 31, 53)18301942
Fibrosis progression - Yes (n=24, 42,31,43)6121211
Fibrosis progression - Missing (n=24, 42, 31, 53)2100
SecondaryNumber of Participants With Epithelial-mesenchymal Transition (EMT) Status

Incidence and severity of EMT status. EMT status was determined centrally using the graft biopsy taken at 3 months. The result was quickly obtained (within 7 to 15 days) and sent to the company in charge of randomization in order to allocate each patient to a treatment group and to provide the investigator with this information without confirming EMT status.

Time frame:
M3 and M12 post transplantation
Reported as:
Number · Participants
Number of Participants With Epithelial-mesenchymal Transition (EMT) Status
ParticipantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
EMT Status at M3-Negative (n=26,43,32,53)043053
EMT Status at M3- Positive (n=26,43,32,53)260320
EMT Status at M3 - Not done (n=26,43,32,53)0000
EMT Status at M12- Negative (n=25,41,32,53)824936
EMT Status at M12- Positive (n=25,41,32,53)17172317
EMT Status at M12- Not done (n=25,41,32,53)0000
SecondaryNumber of Participants With Epithelial-mesenchymal Transition (EMT) Score

Incidence and severity of EMT score. The intensity of EMT markers expression present and detectable in the renal graft at an early stage following transplantation is known as EMT score. EMT score 0 (the best): \<1 EMT score 1 (the better): 1-10% of tubular atrophy EMT score 2: 10-25% of tubular atrophy EMT score 3: 25-50% of tubular atrophy EMT score 4 (the worst): \>50% of tubular atrophy

Time frame:
M3 and M12 post transplantation
Reported as:
Number · participants
Number of Participants With Epithelial-mesenchymal Transition (EMT) Score
participantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
EMT Score 0 at M3 (n= 26,43,32, 53)0 ± 0.4926 ± 0.490 ± 0.7228 ± 0.5
EMT Score 1 at M3 (n= 26,43,32, 53)017025
EMT Score 2 at M3 (n= 26,43,32, 53)170200
EMT Score 3 at M3 (n= 26,43,32, 53)9080
EMT Score 4 at M3 (n= 26,43,32, 53)0040
EMT Score 0 at M12 (n= 25,41,32, 53)1 ± 1.0613 ± 1.170 ± 1.0219 ± 1.03
EMT Score 1 at M12 (n= 25,41,32, 53)711917
EMT Score 2 at M12 (n= 25,41,32, 53)10111012
EMT Score 3 at M12 (n= 25,41,32, 53)4494
EMT Score 4 at M12 (n= 25,41,32, 53)3241
EMT Missing Score at M12 (n= 25,41,32, 53)1200
SecondaryChange in EMT Score

Change (M12 - M3) in EMT Score. Progression in EMT score is defined as an increase by \>=1 of EMT score from M3 to M12. EMT score 0 (the best): \<1 EMT score 1 (the better) : 1-10% of tubular atrophy EMT score 2 : 10-25% of tubular atrophy EMT score 3 : 25-50% of tubular atrophy EMT score 4 (the worst): \>50% of tubular atrophy

Time frame:
M3 and M12 post transplantation
Reported as:
Mean · scores on a scale
Change in EMT Score
scores on a scaleCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
Change in EMT Score-0.3 ± 1.220.9 ± 1.09-0.3 ± 1.050.6 ± 0.99
SecondaryIncidence (Number) of Subclinical Rejections and Borderline Lesions

Incidence of subclinical rejections and borderline lesions with regards to histological evidence of rejection with clinical findings. Subclinical rejections: rejection without clinical symptoms which is diagnosed by chance when a graft biopsy is performed. Clinically suspected BPAR: rejection suspected because of the presence of clinical symptoms (fever, pain, increase of creatinine) and then confirmed by the graft biopsy. Borderline lesions: suspicious for acute T-cell mediated rejection. This category is used when no intimal arteritis is present, but there are foci of tubulitis with minor interstitial infiltration or interstitial infiltration with mild tubulitis.

Time frame:
M3
Reported as:
Number · Participants
Incidence (Number) of Subclinical Rejections and Borderline Lesions
ParticipantsCerticanNeoral
Subclinical rejections-No (n=68, 84)6784
Subclinical rejections- Yes (n=68, 84)10
Subclinical rejections- missing (n=68, 84)11
Clinically suspected BPAR - No (N=68, 84)6884
Clinically suspected BPAR - Yes (N=68, 84)00
Clinically suspected BPAR - Missing (N=68, 84)11
Borderline lesions - No (n=68,84)6271
Borderline lesions - Yes (n=68,84)613
Borderline lesions - Missing (n=68,84)11
SecondaryChange From Baseline (M3) in Estimated Glomerular Filtration Rate (eGFR)

eGFR was calculated according to the abbreviated Modification of Diet in Renal Disease (MDRD) Formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²). LOCF = Last observation carried forward

Time frame:
M3 (baseline) to M12 post transplantation
Reported as:
Least squares mean · mL/min/1.73m^2
Change From Baseline (M3) in Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73m^2CerticanNeoral
without imputation6.99 ± 1.662.54 ± 1.5
imputation by LOCF(96, 97)5.96 ± 1.392.15 ± 1.37
SecondaryChange in Estimated Glomerular Filtration Rate (eGFR) at M12 From Baseline (M3) - ANCOVA Model

The average patient renal function was evaluated on the basis of eGFR was calculated according to the abbreviated MDRD formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²).

Time frame:
Baseline (M3), M12
Reported as:
Mean · mL/min/1.73m²
Change in Estimated Glomerular Filtration Rate (eGFR) at M12 From Baseline (M3) - ANCOVA Model
mL/min/1.73m²Certican EMT+Certican EMT-Neoral EMT+Neoral EMT-
without imputation8.6 ± 15.215.6 ± 18.731.5 ± 9.493.8 ± 10.99
imputation by LOCF (36, 60, 39, 58)-11.9 ± 27.7827.3 ± 138.445.1 ± 40.80-4.9 ± 29.09
SecondaryChange in Urine Protein/Creatinine Ratio (Without Imputation)

One of the factors associated with EMT progression between M3 and M12 according to univariate analysis (ITT biopsies M3 \& M12).

Time frame:
Month 3 (baseline), Month 12
Reported as:
Mean · mg/mmol
Change in Urine Protein/Creatinine Ratio (Without Imputation)
mg/mmolCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
Change in Urine Protein/Creatinine Ratio (Without Imputation)44.4 ± 188.993.5 ± 48.3716.0 ± 41.5329.8 ± 189.41
SecondaryTreatment Failures

A treatment failure is defined as biopsy proven acute rejection (BPAR), a graft loss, a death or a loss to follow up. It was assessed between randomization and 6 and 12 months post-transplantation.

Time frame:
M6 and M12 post transplantation
Reported as:
Number · Number of Participants
Treatment Failures
Number of ParticipantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
M6: Treatment Failure- No33523959
M6: Treatment Failure- Yes3800
M12: Treatment Failure- No29423656
M12: Treatment Failure- Yes71833
M6: BPAR - No33523959
M6: BPAR -Yes3800
M12: BPAR - No29433756
M12: BPAR - Yes71723
M6: Graft Loss - No36603959
M6: Graft Loss - Yes0000
M12: Graft Loss - No35563859
M12: Graft Loss - Yes1410
M6: Death - No36603959
M6: Death - Yes0000
M12: Death - No36603959
M12: Death - Yes0000
M6: Loss to follow-up - No36603959
M6: Loss to follow-up - Yes0000
M12: Loss to follow-up - No36593959
M12: Loss to follow-up - Yes0100
SecondaryType of Biopsy Proven Acute Rejection (BPAR)

A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. Biopsy graded IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).

Time frame:
M6 and M12 post transplantation
Reported as:
Number · Participants
Type of Biopsy Proven Acute Rejection (BPAR)
ParticipantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
Cellular AR - No30463858
Cellular AR - Yes61411
SecondarySeverity of BPAR

A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. Biopsy graded IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).

Time frame:
M6 and M12 post transplantation
Reported as:
Number · Participants
Severity of BPAR
ParticipantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
M6: Banff type Grade IA0200
M6: Banff type Grade IB0400
M6: Banff type Grade IIA1000
M6: Banff type Grade IIB0100
M6: Banff type Grade III0000
M12: Banff type Grade IA2710
M12: Banff type Grade IB2500
M12: Banff type Grade IIA1101
M12: Banff type Grade IIB0100
M12: Banff type Grade III0000
SecondaryIncidence (Number) of BPAR

A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system.

Time frame:
M6 and M12 post transplantation
Reported as:
Number · Number of participants
Incidence (Number) of BPAR
Number of participantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
M6 - No33523959
M6 - Yes3800
M12 - No29433756
M12 - Yes71723
SecondaryIncidence (Number) of Participants With Graft Losses

If a participant underwent a graft nephrectomy, then the day of nephrectomy was considered as the day of graft loss.

Time frame:
M6 and M12 post transplantation
Reported as:
Number · Participants
Incidence (Number) of Participants With Graft Losses
ParticipantsCertican EMT+Certican EMT-Neoral EMT+Neoral EMT-
M6 - No36603959
M6 - Yes0000
M12 - No35563859
M12 - Yes1410

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Neoral—39/98 (39.8%)59/98 (60.2%)
Certican—46/96 (47.9%)59/96 (61.5%)
Most frequent serious events
Showing 10 of 108
Most frequent serious events
EventNeoralCertican
PyrexiaGeneral disorders5/985/96
Kidney transplant rejectionImmune system disorders0/984/96
Urinary tract infectionInfections and infestations2/984/96
Renal failure acuteRenal and urinary disorders4/982/96
DiarrhoeaGastrointestinal disorders3/983/96
PyelonephritisInfections and infestations2/983/96
Pyelonephritis acuteInfections and infestations1/983/96
Bacterial pyelonephritisInfections and infestations3/982/96
Blood creatinine increasedInvestigations3/982/96
AnaemiaBlood and lymphatic system disorders1/982/96
Most frequent other events
Showing 10 of 15
Most frequent other events
EventNeoralCertican
Aphthous stomatitisGastrointestinal disorders3/9817/96
Oedema peripheralGeneral disorders17/9814/96
DyslipidaemiaMetabolism and nutrition disorders6/989/96
Gingival hypertrophyGastrointestinal disorders8/980/96
AnaemiaBlood and lymphatic system disorders6/987/96
DiarrhoeaGastrointestinal disorders3/987/96
Urinary tract infectionInfections and infestations5/987/96
RashSkin and subcutaneous tissue disorders0/987/96
LeukopeniaBlood and lymphatic system disorders7/982/96
Cytomegalovirus infectionInfections and infestations7/982/96

Baseline characteristics

Age, Continuous
Age, Continuous(years)Certican EMT+Certican EMT-Neoral EMT+Neoral EMT-Total
Mean51.2 ± 10.746.4 ± 12.950.0 ± 10.050.7 ± 11.749.3 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Certican EMT+Certican EMT-Neoral EMT+Neoral EMT-Total
Female1717161666
Male19432343128
BMI
BMI(kg/m^2)Certican EMT+Certican EMT-Neoral EMT+Neoral EMT-Total
Mean24.3 ± 4.626.0 ± 4.625.6 ± 4.025.3 ± 4.225.4 ± 4.4
08

Study locations

23 sites
  • Novartis Investigative Site
    Caen, Cedex 14033, France
  • Novartis Investigative Site
    Amiens cedex1, 80054, France
  • Novartis Investigative Site
    Angers, 49 033, France
  • Novartis Investigative Site
    Bordeaux Cedex, 33076, France
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Le Kremlin Bicetre, 94275, France
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Lyon, 69 437, France
  • Novartis Investigative Site
    Nice Cedex 1, 06602, France
  • Novartis Investigative Site
    Paris cedex 15, 75015, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Paris, 75970, France
  • Novartis Investigative Site
    Pierre Benite Cedex, 69495, France
  • Novartis Investigative Site
    Poitiers, 86000, France
  • Novartis Investigative Site
    Reims, 51092, France
  • Novartis Investigative Site
    St Priest en Jarez Cedex, 42277, France
  • Novartis Investigative Site
    Strasbourg, 67091, France
  • Novartis Investigative Site
    Suresnes, 92150, France
  • Novartis Investigative Site
    Toulouse Cedex 4, 31054, France
  • Novartis Investigative Site
    Tours Cedex, 37044, France
  • Novartis Investigative Site
    Vandoeuvre Les Nancys, 54511, France
09

References and documents

Publications

  • Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, Divard G, Jackson AM, Viglietti D, Giral M, Kamar N, Thaunat O, Morelon E, Delahousse M, Kuypers D, Hertig A, Rondeau E, Bailly E, Eskandary F, Bohmig G, Gupta G, Glotz D, Legendre C, Montgomery RA, Stegall MD, Empana JP, Jouven X, Segev DL, Lefaucheur C. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ. 2019 Sep 17;366:l4923. doi: 10.1136/bmj.l4923. Erratum In: BMJ. 2024 Jul 29;386:q1690. doi: 10.1136/bmj.q1690. PubMed 31530561 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2010
First posted
Mar 2, 2010
Start
Sep 2009
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Mar 18, 2014
Last update
Mar 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01079143
Responsible party
Sponsor
First posted
Mar 2, 2010
Start date
Sep 2009
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Mar 18, 2014
Last update
Mar 18, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion